Abstract:
Objective:To observe the clinical curative effect of pulmonary surfactant(PS) in the treatment of neonatal acute respiratory distress syndrome(ARDS).
Methods:From January 2011 to January 2016,86 patients with ARDS in Loudi Central Hospital were involved in this study,and they were randomly divided into the observation group and the control group with 43 cases in each group.The control group was given mechanical ventilation and conventional drug treatment,while the observation group was given endotracheal intubation with pulmonary surfactant treatment of Poractant Alfa Injection in addition to the treatment for control group,1~7 days as a course.The mechanical ventilation time,oxygen time,respiratory index,oxygenation index and clinical effect of the two groups were observed.
Results:The total effective rate of observation group was 90.69%(69.76%,39/43),which was significantly higher than that of control group(30/43),and the difference was statistically significant(P<0.05).In the observation group,mechanical ventilation time,oxygen time,duration of high concentration of oxygen,oxygenation index and respiratory index were more significantly improved compared with those of the control group,the difference being statistically significant(P<0.05).After PS treatment,the incidence of complications was 16.28%(7/43),significantly lower than the control group(44.19%,19/43),and the difference was statistically significant(P<0.05).
Conclusion:In the treatment of ARDS early application of PS can effectively improve oxygenation function,greatly shorten the time of mechanical ventilation and oxygen use,and reduce the incidence of ARDS complications,so it is a safe and effective treatment method for a wide range of clinical promotion.

Key words: Acute respiratory distress syndrome, Pulmonary surfactant, Term, Infant,newborn